This editorial explores the intricate landscape of supplement use in oncology, highlighting the growing interest and challenges surrounding their integration into cancer care. It discusses the disparity in regulatory oversight between supplements and pharmaceutical drugs, the blurred lines in their classification, and the ethical complexities in patient-doctor communication. The importance of transparency, shared decision-making, and realistic expectations is emphasized. While acknowledging the value of traditional research models, the editorial advocates for innovative approaches like retrospective studies, biomarker analysis, and personalized medicine to advance our understanding of supplement efficacy and safety. By integrating these diverse perspectives, we can unlock the full potential of supplements in oncology, ensuring that they are used effectively and responsibly to enhance patient outcomes.
S. Karger AG, Basel.